Cargando…
Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome
Cyclosporine A (CyA) is an effective agent for the treatment of glucocorticoid-dependent idiopathic nephrotic syndrome (GCDNS), but costs are prohibitive in resource-poor societies. The objectives of this study were to evaluate the efficacy and safety of reducing the dose of CyA by co-administering...
Autores principales: | Iyengar, A., Kamath, N., Phadke, K. D., Bitzan, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841509/ https://www.ncbi.nlm.nih.gov/pubmed/24339519 http://dx.doi.org/10.4103/0971-4065.120338 |
Ejemplares similares
-
Urinary indices during relapse of childhood nephrotic syndrome
por: Iyengar, A. A., et al.
Publicado: (2011) -
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016) -
Treatment of Steroid and Cyclosporine-Resistant Idiopathic Nephrotic Syndrome in Children
por: Nikibakhsh, A. A., et al.
Publicado: (2011) -
Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome
por: Dorresteijn, Eiske M., et al.
Publicado: (2008) -
Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction
por: GAO, XIANG, et al.
Publicado: (2014)